Clinical trial phase III of RUBY, using Jemperli (dostarlimab) with chemotherapy for treating endometrial cancer, successfully reaches endpoint in enhancing overall patient survival rate.

NovelMed Therapeutics kicks off its Phase II trial for untreated Paroxysmal Nocturnal Hemoglobinuria (PNH) patients. The primary investigation will be on the anti-Bb antibody NM8074 through a comprehensive study, aiming to evaluate its safety and efficiency in PNH patients.

Novartis published positive early results from the critical Phase III ALIGN trial midpoint evaluation, studying atrasentan, an oral ERA for treating people with IgA nephropathy.

Innovent reports substantial weight reduction, several metabolic advantages, and a good safety record with a higher dose of 9 mg Mazdutide (IBI362) following a 48-week trial in phase 2 study for obesity.

Merck KGaA, Darmstadt, has formed a strategic partnership with Jiangsu Hengrui Pharmaceuticals Co. Ltd. It holds a global exclusive license to develop, manufacture, and distribute Hengrui’s advanced PARP1 trapping inhibitor HRS-1167.

Coherus BioSciences, Inc. along with Shanghai Junshi Biosciences Co., Ltd. revealed that the FDA has given its approval for LOQTORZI™ (toripalimab-tpzi) to be used with cisplatin and gemcitabine.

Kymera Therapeutics discloses initiation of Phase 2 trial with KT-474 (SAR444656), a novel IRAK4 degrader, being administered to its first Hidradenitis Suppurativa patient.

Otsuka Pharmaceutical, including its U.S. division, reported promising results from two Phase 3 trials evaluating centanafadine's efficacy and safety in managing ADHD in children and teens.

ImmunoGen Discloses European Medicines Agency Approval of Mirvetuximab Soravtansine's Marketing Authorization Application for Dealing with Platinum-Resistant Ovarian Cancer.

TransCode Therapeutics, Inc., an RNA oncology specialist, today announced improved survival rates in mouse models with human glioblastoma multiforme tumors after treatment with their leading candidate, TTX-MC138.

Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.

Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.